MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$8,968K
Net Income
-$43,816K
Net Profit Margin
-488.58%
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue
8,968
4,210
2,781
12,768
Research and development
47,964
44,069
41,979
36,678
General and administrative
10,134
10,175
10,517
9,065
Total operating expenses
58,098
54,244
52,496
45,743
(loss) income from operations
-49,130
-50,034
-49,715
-32,975
Interest income
5,916
5,591
3,689
2,746
Foreign currency exchange loss
25
-8
-50
-29
Gain on disposal of property and equipment
0
0
0
0
Total other income
5,941
5,583
3,639
2,717
Net (loss) income before income taxes
-43,189
-44,451
-46,076
-30,258
Income tax provision
208
52
59
-3,177
Net (loss) income
-43,397
-44,503
-46,135
-27,081
Provision for pension benefit obligation
-54
-55
-690*
53
Unrealized gain (loss) on available-for-sale securities
-
-
-
73
Unrealized loss on available-for-sale securities
473
974
-110*
-
Comprehensive (loss) income
-43,816
-45,422
-46,715
-26,955
Basic Average Shares
101,478,945
99,883,878
85,551,500
82,397,753
Diluted Average Shares
101,478,945
99,883,878
84,743,796
82,397,753
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive (loss) income
-$43,816K
(-255.10%↓ Y/Y)
Provision for pension
benefit obligation
-$54K
(-201.89%↓ Y/Y)
Net (loss) income
-$43,397K
(-252.96%↓ Y/Y)
Unrealized loss on
available-for-sale securities
$473K
(387.63%↑ Y/Y)
Interest income
$5,916K
(92.83%↑ Y/Y)
Foreign currency
exchange loss
$25K
(-98.20%↓ Y/Y)
Net (loss) income
before income taxes
-$43,189K
(-289.23%↓ Y/Y)
Income tax provision
$208K
(-82.65%↓ Y/Y)
Total other income
$5,941K
(33.27%↑ Y/Y)
(loss) income from
operations
-$49,130K
(-215.87%↓ Y/Y)
Collaboration revenue
$8,968K
(-61.33%↓ Y/Y)
Total operating
expenses
$58,098K
(49.94%↑ Y/Y)
Research and development
$47,964K
(56.47%↑ Y/Y)
General and
administrative
$10,134K
(25.19%↑ Y/Y)
Buy us a coffee
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)